Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia

Abstract Introduction: We aimed to compare outcomes of patients with AML treated with frontline hypomethylating agent and venetoclax (HMA + Ven) who achieved complete remission (CR), complete remission with partial hematologic recovery (CRh), complete remission with incomplete hematologic recovery (...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2024-09
Main Authors: Jain, Akriti G., Volpe, Virginia O., Wang, Chen, Ball, Somedeb, Tobon, Katherine, Chan, Onyee, Padron, Eric, Kuykendall, Andrew, Lancet, Jeffrey E., Komrokji, Rami, Sallman, David A., Sweet, Kendra L.
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Introduction: We aimed to compare outcomes of patients with AML treated with frontline hypomethylating agent and venetoclax (HMA + Ven) who achieved complete remission (CR), complete remission with partial hematologic recovery (CRh), complete remission with incomplete hematologic recovery (CRi), or morphologic leukemia-free state (MLFS) as defined by ELN 2022. Methods: Patients with AML seen at Moffitt Cancer Center between 2018 and 2022 and treated with HMA + Ven were retrospectively evaluated. Results: About 120 patients achieved blast clearance with best response of CR in 52 (43.3%), CRh in 22 (18.3%), CRi in 31 (25.8%) and MLFS in 15 (12.5%) patients. Greater proportion of patients with MLFS had a prior myeloid malignancy ( p = 0.003) and were treated with prior HMA ( p < 0.001). Patients that achieved MLFS as their best response had inferior OS compared to the CR/CRh/CRi cohort (8 months vs. 27 months; p < 0.001). RFS was also worse for the MLFS cohort. Conclusion: To the best of our knowledge, this is the largest study analyzing differences in outcomes of AML patients treated with HMA + Ven based on best response. We noted that prior myeloid malignancy and use of HMA led to more MLFS as best response compared to CR/CRi. The OS and RFS were inferior for MLFS cohort.
ISSN:0939-5555
1432-0584
1432-0584
DOI:10.1007/s00277-024-05976-6